摘要
背景:多发性骨髓瘤患者患有免疫系统失调,针对免疫系统(例如单克隆抗体或特异性细胞治疗如CAR-T细胞)的新治疗方案进入临床实践,但是耗尽的免疫系统阻碍了更有效的免疫治疗。针对微环境中的免疫功能障碍可能是免疫介导治疗的潜在靶标。 方法:在这里,我们回顾当前关于在耗尽的T和B细胞表面表达的程序性死亡1(PD-1)受体的文献和知识,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导细胞凋亡。 结果:程序性死亡1(PD-1)受体在耗尽的T和B细胞表面表达,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导的细胞凋亡。近来,通过单克隆抗体抑制这种“检查点”已经显示在实体瘤和恶性淋巴瘤中的高活性。在多发性骨髓瘤患者中,PD-L1在骨髓瘤细胞上过表达,PD1在T细胞上表达,表明PD-1 / PD-L1在免疫抑制微环境中起主要作用。 结论:使用抗PD-1 / PD-L1策略的免疫治疗是多发性骨髓瘤患者的有希望的治疗方案。
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
图形摘要
Current Cancer Drug Targets
Title:Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Volume: 17 Issue: 9
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
摘要: Background: Patients with Multiple Myeloma suffer from dysregulation of the immune system and new therapeutic options targeting the immune systems such as monoclonal antibodies or specific Cell therapy such as CAR-T cells have entered clinical practice, but the exhausted immune system hampered a more effective immunotherapy. Targeting the immunological dysfunction in the microenviroment might be a potential target for immune-mediated therapies.
Method: Here we review the current literature and knowledge about the programmed death 1 (PD-1) receptor which is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits T cell-mediated apoptosis.
Results: The programmed death 1 (PD-1) receptor is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits Tcell-mediated apoptosis. Inhibiting such “checkpoint” by monoclonal antibodies recently has been shown high activity in solid tumors and malignant lymphomas. In patients with multiple myelomaPD-L1 is overexpressed on myeloma cells and PD1 on T-cells suggesting an active role of PD-1/PD-L1 in the immunosuppressive microenvironment.
Conclusion: Immunotherapies using anti-PD-1/PD-L1 strategies are a promising treatment options for patients with multiple myeloma.
Export Options
About this article
Cite this article as:
Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170906170348
DOI https://dx.doi.org/10.2174/1568009617666170906170348 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Biomarkers of Atrial Fibrillation in Hypertension
Current Medicinal Chemistry Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Life-history Constraints on the Mechanisms that Control the Rate of ROS Production
Current Genomics Electrophysiologic Considerations After Sudden Cardiac Arrest
Current Cardiology Reviews Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Mechanism-based Modulator Discovery for Sirtuin-catalyzed Deacetylation Reaction
Mini-Reviews in Medicinal Chemistry Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Getting to the Heart of the Matter: Exploring Opportunities for Gene Therapy Treatment of Dystrophic Cardiomyopathy
Current Gene Therapy Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Urinary Steroids Measured by Modern Separation Techniques and Applied as Biomarkers in Stress Studies
Current Pharmaceutical Analysis The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets